Molecular Partners Publishes Invitation to Annual General Meeting 2023
13 mars 2023 09h30 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022
09 mars 2023 16h00 HE
|
Molecular Partners
Research & Development Highlights: Initiated Phase 1 study of MP0533, a novel tri-specific T-cell engager for the treatment of acute myeloid leukemia (AML) and high risk myelodysplastic syndrome...
Molecular Partners to Hold Conference Call to Discuss Fourth Quarter and Full Year 2022 Results and Present at the 43rd Annual Cowen Health Care Conference
02 mars 2023 16h00 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Presents New Preclinical Data Supporting Its Radio DARPin Therapy Platform
28 févr. 2023 01h15 HE
|
Molecular Partners
Proprietary Radio DARPin Therapy Platform designed to deliver high amount of radioactivity to the tumor while maintaining low accumulation in other tissues Data reveal engineering approach to...
Molecular Partners to Present at SVB Leerink Global Healthcare Conference
10 févr. 2023 01h00 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Initiates Clinical Study of Trispecific Candidate MP0533 for the Treatment of Acute Myeloid Leukemia
16 janv. 2023 01h00 HE
|
Molecular Partners
Unique avidity driven mechanism engages CD3 on T cells when binding either two or three tumor-associated antigens to enhance selectivity for AML cellsPreclinical data demonstrated that MP0533 can...
Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference
08 janv. 2023 15h00 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR : Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
Molecular Partners to Present at 41st Annual JP Morgan Healthcare Conference and Swiss Investor Conferences
30 déc. 2022 01h00 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML
12 déc. 2022 19h00 HE
|
Molecular Partners
New data indicates potential to expand the therapeutic window and improve safety compared to existing T-cell engagersTri-specific T-cell engager resulted in AML cell-specific cytotoxicity with minimal...
Molecular Partners Presents Positive Interim Safety and Mechanistic Data From Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors
10 nov. 2022 01h00 HE
|
Molecular Partners
First clinical observation of tumor localized CD40 activation provided by MP0317No systemic or dose-limiting toxicities observed, a key parameter for CD40 agentsDose escalation remains ongoing with...